Alignment Healthcare vs Clover Health Investments
ALHC and CLOV side by side, both in accident and health insurance and medical. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ALHC and CLOV compare
Clover Health Investments is the larger company, worth 1.6 times as much as Alignment Healthcare ($2.6B against $1.6B).
On earnings, Alignment Healthcare is cheaper: it trades at 69.9× trailing earnings, against 497× for Clover Health Investments.
Clover Health Investments grew revenue faster over the last twelve months (54.5% versus 35.9% for Alignment Healthcare).
Alignment Healthcare keeps more of each dollar of sales as profit, with a net margin of 0.59% compared with 0.45% at Clover Health Investments.
Alignment Healthcare scores higher on the StockData Score (9 against 6 for Clover Health Investments), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ALHC | CLOV |
|---|---|---|
| Size and price | ||
| Market cap | $1.6B | $2.6B |
| Share price | $7.69 | $4.97 |
| Change, 1 year | −53.1% | 91.2% |
| Change, 5 years | −64.6% | −13.6% |
| Beta (5Y) | 0.82 | 1.66 |
| Employees | 1,849 | 724 |
| StockData Score | ||
| Total score | 9 (better) | 6 |
| Valuation score | 1 (better) | 0 |
| Growth score | 2 | 3 (better) |
| Performance score | 3 (better) | 2 |
| Health score | 3 (better) | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 69.9× (better) | 497× |
| P/S | 0.3× (better) | 1.0× |
| P/B | 5.8× (better) | 6.8× |
| EV/EBITDA | 15.8× (better) | 182× |
| P/FCF | 20.9× | 20.0× (better) |
| FCF yield | 4.8% | 5.0% (better) |
| Fair value | $5.06 | – |
| Margin of safety | −51.9% | – |
| Growth | ||
| Revenue growth (TTM) | 35.9% | 54.5% (better) |
| Revenue growth, 5Y average | 32.7% (better) | 23.4% |
| Profitability | ||
| Operating margin | 0.88% (better) | 0.45% |
| Net margin | 0.59% (better) | 0.45% |
| FCF margin | 1.6% | 4.8% (better) |
| Return on equity | 13.2% (better) | 3.4% |
| Return on invested capital | – | 9.6% |
| Financial health | ||
| Debt / equity | 1.17 | – |
| Net debt / EBITDA | −5.57 | – |
| Interest coverage | 2.6× | – |
| Current ratio | 1.71 (better) | 1.55 |
| Altman Z-score | 4.27 (better) | 4.22 |
| Piotroski F-score | 5 (better) | 3 |
| Dividends and buybacks | ||
| Buyback yield | – | 0.00% |
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 106% | 27.5% |
| Held by insiders | 4.6% | 23.5% |
| Insider net buying, 12 months | −$517M | −$8.7M (better) |
| Short interest, % of float | 11.6% | 5.7% |
Go deeper
- ALHC stock overview
- ALHC income statement
- ALHC valuation and score
- CLOV stock overview
- CLOV income statement
- CLOV valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.